臨床外科66巻7号

2011年07月発行

特集 術前薬物療法は乳癌手術を縮小させるか

術前分子標的薬物療法と乳房温存術

著者： 齋藤雄紀¹ 大下内理紗¹ 寺尾まやこ¹ 寺田瑞穂¹ 津田万里¹ 岡村卓穂¹ 鈴木育宏¹ 徳田裕¹

所属機関： ¹東海大学医学部外科学系乳腺・内分泌外科

ページ範囲：P.914 - P.918

【ポイント】

◆HER 2陽性乳癌のトラスツズマブ併用術前薬物療法は高いpCRが期待されるが，わが国では保険適応外使用である．

◆新規抗HER 2治療薬を併用した術前薬物療法の臨床試験が進行している．

◆高いpCR率を乳癌縮小手術に反映させるため，術前薬物療法後の残存腫瘍をより正確に評価する診断法を確立しなければならないなど検討課題は多い．

参考文献

1）Wolmark N, Wang J, Mamounas E, et al：Preoperative chemotherapy in patients with operable breast：nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monographs 30：96-102, 2001

2）Fisher B, Bryant J, Wolmark N, et al：Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16：2672-2685, 1998

3）Bear HD, Anderson S, Smith RE, et al：Sequential preoperative or postoperative decetaxle added to preoperative doxorubicine plus cyclophosphamide for operable breast cancer：National Surgical Adjuvant Breast and Bowel Project B-27. J Clin Oncol 24：2019-2027, 2005

4）日本乳癌学会（編）：科学的根拠に基づく乳癌診療ガイドライン[1]薬物療法．2010年版．金原出版，2010，pp15-18

5）Buzdar AU, Ibrahim NK, Francis D, et al：Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamid chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cacer：an update of the initial randomized study population and date of additional patients treated with the same regimen. Clin Cancer Res 13：228-233, 2007

6）Gianni L, Eiermann W, Semiglazov V, et al：Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER 2-positive lically advanced breast cancer（the NOAH trial）：a randomized controlled superiority trial with a parallel HER 2-negative cohort. Lancet 375：377, 2010

7）Untch M, Rezai M, Loibl S, et al：Neoadjuvant treatment with trastuzumab in HER 2-positive breast cancer：results from the GeparQuattro study. J clin Oncol 28：2024-2031, 2010

8）NCCN clinical practice guideline. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

9）Untch M, Loibl S, Bischoff J, et al：Lapatinib vs trastuzumabu in combination with neoadjuvant anthracycline-taxane-based chemotherapy：Primary efficacy endopoint analysis of the GEPARQUINTO STUDY（GBG44）. Cancer Research 70（suppl）：81s, Abst. #S3-1, 2010

10）Baselga J, Bradbury I, Eidtmann H, et al：First results of the NeoALTTO trial（BIG 01-06/EGF 106903）：A phase Ⅲ, randomized, open label, neoadjuvant study of Lapatinib, Trastuzumab, and their combination plus Paclitaxel in women with HER 2-positive primary breast cancer. Cancer Research 70（suppl）：82s, Abst. #S3-3, 2010

11）Gianni L, Pienkowski T, Im Y-H, et al：Neoadjuvant pertuzumab（P）and trastuzumab（H）：Antitumor and safety analysis of a randomized phase Ⅱ study（‘NeoSphere’）. Cancer Research 70（suppl）：82s, Abst. #S3-2, 2010